ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM.
Open access · greenAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 95 citations in OpenAlex.
- Metabolic plasticity and optimal redox homeostasis are essential for efficient metastatic colonization.Molecular metabolism · 2026Article
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non-small cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- The Crosstalk Between Epithelial-Mesenchymal Transition and Anoikis Resistance: A New Perspective of Traditional Chinese Medicine to Prevent Tumor Metastasis.Drug design, development and therapy · 2026Review
- Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025Review
- Epithelial-mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC).Cancer pathogenesis and therapy · 2025Review
- Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review.Anti-cancer drugs · 2025Review
- SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancers.PloS one · 2025Article
- Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target.National science review · 2024Article
- Beauvericin Reverses Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells through Regulation of Notch Signaling and Autophagy.ACS pharmacology & translational science · 2024Article
- Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands) · 2024Review
- Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.Scientific reports · 2024Article
- 5-Fluorouracil dose escalation generated desensitized colorectal cancer cells with reduced expression of protein methyltransferases and no epithelial-to-mesenchymal transition potential.Oncology research · 2024Article
- ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.International journal of molecular sciences · 2023Review
- Comprehensive analysis of suppressor of cytokine signaling 2 protein in the malignant transformation of NSCLC.Experimental and therapeutic medicine · 2023Article
- IKKα promotes lung adenocarcinoma growth through ERK signaling activation via DARPP-32-mediated inhibition of PP1 activity.NPJ precision oncology · 2023Article
- Endogenous and imposed determinants of apoptotic vulnerabilities in cancer.Trends in cancer · 2023Review
- Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.Oncology letters · 2022Review
- Targeting apoptosis to manage acquired resistance to third generation EGFR inhibitors.Frontiers of medicine · 2022Review
- A data-assimilation approach to predict population dynamics during epithelial-mesenchymal transition.Biophysical journal · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
30 authors at 2 institutions in 1 country.
Kyung-A Song *Philips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Matthew J Niederst *Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Timothy L LochmannPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Aaron N HataMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Hidenori KitaiDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Jungoh HamPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Konstantinos V FlorosPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Mark A HicksPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Haichuan HuMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Hillary E MulveyMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Yotam DrierMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Daniel A R HeiseyPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Mark T HughesPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Neha U PatelPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Elizabeth L LockermanMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Angel GarciaMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Shawn GillepsieMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Hannah L ArchibaldMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Maria Gomez-CaraballoMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Tara J NultonPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Brad E WindlePhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia.
Zofia PiotrowskaMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Sinem E SahingurDepartment of Periodontics, VCU School of Dentistry, Virginia Commonwealth University, Richmond, Virginia.
Shirley M TaylorDepartment of Microbiology and Immunology, Massey Cancer Center, Richmond, Virginia.
Mikhail DozmorovDepartment of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Bradley BernsteinMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Hiromichi EbiDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Jeffrey A EngelmanMassachusetts General Hospital Cancer Center, Boston, Massachusetts. acfaber@vcu.edu jeffrey.engelman@novartis.com.
Anthony C FaberPhilips Institute for Oral Health Research, VCU School of Dentistry and Massey Cancer Center, Richmond, Virginia. acfaber@vcu.edu jeffrey.engelman@novartis.com.
Harvard University · USMassachusetts General Hospital · US
Funding
Microbial Nucleic Acid Sensing in PeriodontitisR01DE025037 · NIDCR · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAHINGUR, SINEM ESRA · 2015 to 2019
$1.9MEvolution of resistance of EGFR mutant non-small cell lung cancerK08CA197389 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N · 2016 to 2020
$896kAssessing BIM expression as a cause and marker for resistance to targeted therapiK22CA175276 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FABER, ANTHONY CHARLES · 2014 to 2016
$573kNCI NIH HHS K08 CA197389NCI NIH HHS K22 CA175276NIDCR NIH HHS R01 DE025037
Abstract
PubMed holds no abstract for this paper.
Indexed as
Molecular Targeted TherapyAniline CompoundsAnimalsApoptosisBcl-2-Like Protein 11Cell CycleDisease Models, AnimalDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsGene Expression Regulation, NeoplasticHumansLung NeoplasmsMiceMutationPromoter Regions, GeneticAniline CompoundsBcl-2-Like Protein 11ErbB ReceptorsnavitoclaxProtein Kinase InhibitorsRNA, Small InterferingSulfonamides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.